A practical guide on the use of imiquimod cream to treat lentigo maligna

2021 ◽  
Author(s):  
Pascale Guitera ◽  
Andreanne Waddell ◽  
Elizabeth Paton ◽  
Gerald B Fogarty ◽  
Angela Hong ◽  
...  
Keyword(s):  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Practical Guide

Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study

2016 ◽  
Vol 74 (1) ◽  
pp. 81-87.e1 ◽  
Author(s):  
Mirja Gautschi ◽  
Patrick A. Oberholzer ◽  
Marc Baumgartner ◽  
Karolina Gadaldi ◽  
Nikhil Yawalkar ◽  
...  
Keyword(s):  
Prognostic Markers ◽  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Follow Up Study ◽  
Long Term Follow Up

A pilot study of treatment of lentigo maligna with 5% imiquimod cream

2004 ◽  
Vol 151 (2) ◽  
pp. 485-488 ◽  
Author(s):  
C.J. Fleming ◽  
A.M. Bryden ◽  
A. Evans ◽  
R.S. Dawe ◽  
S.H. Ibbotson
Keyword(s):  
Pilot Study ◽  
Lentigo Maligna ◽  
Imiquimod Cream

Histologic Resolution of Melanoma In Situ (Lentigo Maligna) With 5% Imiquimod Cream

2003 ◽  
Vol 139 (7) ◽  
Author(s):  
M. Shane Chapman ◽  
Steven K. Spencer ◽  
Jeoffry B. Brennick
Keyword(s):  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Melanoma In Situ

Topical 5% Imiquimod in the Treatment of Lentigo Maligna

2012 ◽  
Vol 16 (4) ◽  
pp. 245-249 ◽  
Author(s):  
Jessica G. Wong ◽  
Jack W.P. Toole ◽  
Alain A. Demers ◽  
Grace Musto ◽  
Marni C. Wiseman
Keyword(s):  
Effective Treatment ◽  
Tumor Size ◽  
Treatment Duration ◽  
Standard Treatment ◽  
Surgical Excision ◽  
Off Label Use ◽  
Lentigo Maligna ◽  
Imiquimod Cream ◽  
Off Label ◽  
The Mean

Background: Standard treatment for lentigo maligna (LM) is surgical excision with 5 to 10 mm margins. This can be cosmetically disfiguring. Imiquimod locally induces Toll-like receptors to release cytokines that destroy neoplastic melanocytes. Objective: The off-label use of topical 5% imiquimod cream may provide an alternative to surgery. This study reviews the use of imiquimod to treat LM. Methods: A 5-year retrospective and prospective chart analysis was conducted. Pretreatment biopsies confirmed the diagnosis. Treatment was individualized for each patient. Posttreatment biopsies and dermoscopy determined clearance of LM. Results: Twenty-seven patients were reviewed. There were 20 responders (74.1%) and 7 failures. The mean tumor size (area of an ellipse) was 6.69 cm2, and the mean treatment duration was 17.68 weeks. Neither the size of the tumor ( p = .86) nor treatment duration ( p = .18) was related to resolution of the lesion. Conclusion: Imiquimod is an effective treatment for LM that provides patients with a cosmetically favorable outcome when standard surgery is not an option.

Sign in / Sign up

Export Citation Format

Share Document